Objective: To determine the pathogenic mechanisms of autoantibodies to the cell adhesion molecule Caspr2 in acquired neuromyotonia and autoimmune encephalitis. Methods: Caspr2-positive samples were confirmed using a cell-based assay, and their IgG subtypes were determined by enzyme-linked immunosorbent assay and cell-based assay. A solid phase binding assay quantified the binding of Caspr2 to contactin-2 in the presence of Caspr2 autoantibodies. Living cultures of primary rat hippocampal neurons were incubated with Caspr2-positive or control sera, and the distribution of Caspr2-positive immunofluorescent puncta and total surface Caspr2 was quantified. HEK cells transfected to express Caspr2 were incubated with Caspr2-positive or control samples, and cell-surface biotinylation and Western blot were used to assess total, internalized, and surface levels of Caspr2. Results: We confirmed 6 samples with strong Caspr2 reactivity. IgG4 Caspr2 antibodies were present in all 6 cases. Caspr2 interacted with another cell adhesion molecule, contactin-2, with nanomolar affinity in the solid phase assay, and Caspr2 autoantibodies inhibited this interaction. Caspr2 autoantibodies did not affect the surface expression of Caspr2 in rat primary hippocampal neurons or transfected HEK cells. Interpretation: Caspr2 autoantibodies inhibit the interaction of Caspr2 with contactin-2 but do not cause internalization of Caspr2. Functional blocking of cell adhesion molecule interactions represents a potential mechanism with therapeutic implications for IgG4 autoantibodies to cell adhesion molecules in neurological diseases.
C ontactin-associated protein-like 2 (Caspr2) is a cell adhesion molecule (CAM) of the neurexin family, and is expressed on central nervous system (CNS) and peripheral nervous system (PNS) axons. 1 Autoantibodies to surface epitopes of Caspr2 have been associated with a form of acquired peripheral nerve hyperexcitability (acquired neuromyotonia or Isaacs syndrome) and autoimmune encephalitis. [2] [3] [4] Some patients with Caspr2 autoantibodies have both CNS and PNS involvement (Morvan syndrome), which is characterized by neuromyotonia, encephalitis, dysautonomia, insomnia, and/or neuropathic pain. 4 Caspr2 is localized to the juxtaparanodal region of both CNS and PNS nodes of Ranvier, 1 which are regions of cellular specializations between myelinating glial cells and axons that enable saltatory conduction of action potentials. 5, 6 Nodes of Ranvier consist of 3 domains: the node, the paranode, and the juxtaparanode. At the juxtaparanodes, contactin-2 (also known as TAG-1) interacts with Caspr2, and this association is necessary for the clustering of voltage-gated potassium channels (VGKCs). 7, 8 Antibody-mediated crosslinking and internalization is a common mechanism of autoantibodies targeting ionotropic receptors, including the N-methyl-D-aspartate receptor (NMDAR) and the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) in autoimmune encephalitis. [9] [10] [11] [12] [13] [14] However, diseases caused by autoantibodies to CAMs may not share this mechanism. Caspr2 autoantibodies are frequently of the IgG4 subtype, 3, 4, 15 as are autoantibodies to other CAMs expressed on nodes of Ranvier, such as neurofascins and contactin. [16] [17] [18] [19] IgG4 has several unique characteristics not found in other IgG subtypes. IgG4 antibodies have low affinities for Fcc receptors and are ineffective in activating complement. IgG4 have high affinities for their antigens as they undergo a higher number of somatic hypermutations. Finally, IgG4 undergo hemiantibody exchange, making each antibody functionally monovalent. 17, 20 Thus, crosslinking and internalization of the target antigen in these disorders is less likely. A different paradigm may be needed to understand the pathophysiology of IgG4 autoantibodies to CAMs. In this paper, we demonstrate that autoantibodies to Caspr2 do not cause its internalization, and thus do not function in a manner similar to autoantibodies against ionotropic receptors such as NMDAR. Rather, Caspr2 autoantibodies disrupt the binding of Caspr2 to contactin-2, potentially interfering with the clustering of VGKCs at juxtaparanodes and resulting in hyperexcitability of peripheral nerves. This potential mechanism of Caspr2 autoantibodies serves as a paradigm for pathogenicity of IgG4 autoantibodies to other CAMs in the CNS and PNS. 
Subjects and Methods

Cell-Based Assay
Serum samples were tested for Caspr2 antibodies using methods previously described. 2 Briefly, human embryonic kidney 293 (HEK293) cells were transiently transfected using Lipofectamine 3000 (Invitrogen, Carlsbad, CA) and a plasmid containing human Caspr2 in a Prk5 vector (gift from Dr Elior Peles, Weizmann Institute of Science, Rehovot, Israel). Sera were heatinactivated by incubating at 558C for 30 minutes, then were applied (1:100) to live cells for 30 minutes at 378C. Cells were washed, permeabilized, and stained with commercial rabbit antibody against Caspr2 at a dilution of 1:200 (Abcam, Cambridge, MA; cat. # ab33994), followed by fluorescently conjugated secondary antibodies. Images of transfected cells were taken with a Leica (Wetzlar, Germany) SP5 confocal microscope at 3 20 magnification. Six samples with strong Caspr2 reactivity were chosen for further experimentation. The Caspr2 antibody titer of these 6 samples was determined using serial dilutions of heat-inactivated sera applied to live HEK293 cells transfected to overexpress Caspr2 as above.
IgG Subtyping of Caspr2 Autoantibodies
The 
Solid Phase Binding Assays
Binding of Caspr2 to contactin-2 was determined using a protocol modified from Lu et al. 22 Recombinant peptide of the To determine whether Caspr2 autoantibodies interfere with Caspr2 binding to contactin-2, human Caspr2 peptide was immobilized onto a 96-well plate, and blocked with blocking buffer as above. After the blocking step, patient sera with Caspr2 autoantibodies and control sera were applied at concentrations ranging from 1:10 to 1:100 for 1 hour (in duplicate). After washing the plate, wells were incubated with human contactin-2 (200ng) in wash buffer for 1 h. Wells were then incubated with anti-contactin-2 (R&D Systems, 1:1,000) for 1 hour followed by HRP-conjugated donkey anti-sheep IgG preadsorbed to human IgG (Santa Cruz Biotechnology, 1:2,000). Samples were developed and read as outlined above. For all experimental conditions, control samples with immobilized Caspr2 and human sera (without contactin-2) were subtracted to account for a small amount of cross-reactivity of the secondary antibody to human IgG.
Immunofluorescence and Quantification of Cell-Surface Caspr2
Rat hippocampal neuronal cultures were prepared and immunohistochemical experiments were performed to study surface expression of Caspr2 based on a modified protocol initially used to study internalization of NMDARs. 10 Briefly, rat hippocampal neurons were cultured for 14 to 21 days on coverslips then treated for 24 hours at 378C with heat-inactivated sera (1:100 or 1:25) containing Caspr2 autoantibodies versus sera from controls who had inherited neuropathy. To visualize Caspr2 on the cell surface, live neurons were incubated with a polyclonal antibody to the extracellular domain of Caspr2 (R&D Systems, cat. # AF5145, 1:200) for 30 minutes at 378C. After removing the media and washing with phosphate-buffered saline (PBS), neurons were fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, incubated with a monoclonal antibody to the C-terminal (intracellular) portion of Caspr2 (Abcam, cat. # 33994,1:200), washed, and incubated with appropriate fluorescently conjugated secondary antibodies. A minimum of 3 replicates were performed for each experimental condition.
Images were captured on a Leica SP5 confocal microscope at 3 63 magnification with a step size of 0.34 mm. Images were thresholded and Caspr2 puncta were quantified using SynPAnal software. 23 For each image, 50 mm axonal segments (n 8) were manually traced and the puncta (minimum 4nm diameter) were automatically quantified for each segment. A minimum of 3 replicates with a minimum of 4 images per replicate were analyzed for each experimental condition for a minimum of 96 analyzed segments for each experimental condition. Cell-surface Caspr2 density, area, and fluorescence intensity are defined as the puncta stained by the polyclonal Caspr2 antibody to the extracellular domain that colocalize with the monoclonal (C-terminal) Caspr2 antibody to minimize nonspecific activity of the polyclonal antibody. Internalized Caspr2 was quantified as Caspr2 that was stained with the C-terminal antibody but was not stained with the antibody to the extracellular domain (total Caspr2 minus surface Caspr2).
Cell-Surface Biotinylation
HEK293 cells were cultured in 6-well plates and transfected to express human Caspr2. Cells were treated with anti-Caspr2 or control sera as above for 24 hours at 378C. Biotinylation and isolation of surface Caspr2 were performed using Pierce Cell Surface Protein Isolation Kit (Thermo Fisher Scientific) according to manufacturer protocol. Briefly, cells were quickly washed with ice-cold PBS, incubated with NHS-SS-biotin (0.25mg/ml) for 30 minutes at 48C, and quenched. Cells were then scraped, transferred, to a 15ml conical tube, and centrifuged at 500 3 g for 3 minutes. The pellet was lysed in RIPA buffer, sonicated for 5 seconds, and centrifuged at 10,000 3 g for 2 minutes at 48C. The supernatant was incubated with NeutrAvidin Agarose for 60 minutes. Sample was centrifuged for 1 minute at 1,000 3 g. Supernatant was collected separately. Cell surface proteins were eluted from agarose with 1mM dithiothreitol. Total, internalized, and surface levels of Caspr2 were determined using sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blot. Samples were run on 4 to 15% linear gradient gels (Bio-Rad Laboratories, Hercules, CA) and transferred to nitrocellulose membrane. Membranes were blocked in 5% nonfat dried milk in PBS containing 0.05% Tween-20, then incubated with rabbit anti-Caspr2 (Abcam, cat. # ab137052, 1:1,000) or mouse anti-actin (Abcam, cat. # ab3280, 1:1,000) overnight at 48C. After rinsing, the membranes were incubated in peroxidase-conjugated secondary antibody for 1 hour at room temperature. Reactivity was visualized using enhanced chemiluminescence substrate. Blots were developed with the ChemiDoc Imaging System (Bio-Rad Laboratories). Images were inverted and densitometry quantified using Fiji software (NIH, Bethesda, MD). Caspr2 expression was normalized to that of actin. Three replicates of each experimental condition were performed.
Statistics
SigmaStat software (Systat Software, Chicago, IL) was used for all statistical tests. Comparisons were made using a t test or 1-way analysis of variance followed by Holm-Sidak post hoc analysis as indicated. Data were expressed as mean 6 standard error of the mean, and significance was set at p < 0.05.
Results
Caspr2 Autoantibodies Are Predominantly IgG4
Samples from 5 patients with acquired neuromyotonia and/or encephalitis that were previously determined to be Caspr2 antibody-positive were confirmed as positive by CBA. One additional case did not have reported neuromyotonia or encephalitis but presented with neuropathic pain. These 6 samples are designated C1 to C6. Heat-inactivated sera from these cases were tested a 1:100 dilution on live HEK cells transfected to express Caspr2 (Fig  1) . To determine the Caspr2 antibody titer of each sample, serial dilutions were performed. The clinical characteristics and Caspr2 antibody titers of these cases are outlined in Table 1 .
Previous work has demonstrated that Caspr2 autoantibodies are frequently of the IgG4 isotype. 3, 4, 15 To determine the IgG composition of anti-Caspr2 autoantibodies in our case samples, we created a solid phase binding assay and tested the bound IgG with IgG subtype-specific secondary antibodies. All 6 case samples, but not control samples, contained IgG reactivity to Caspr2 in the assay. All 6 case samples contained IgG4 anti-Caspr2 autoantibodies, and IgG4 was the predominant subtype in 5 of 6 sera ( Table 2 ). The exception was sample C2, which had a mixture of IgG2 > IgG4 > IgG1. IgG subtyping was confirmed by CBA (Fig 2) for 3 of 6 samples. Again, Caspr2 antibodies were predominantly of the IgG4 subtype. For the remaining samples, the presence of IgG4 antibodies by CBA has been previously reported.
21
Caspr2 Binds Contactin-2 In Vitro Next, we studied the interaction of Caspr2 with contactin-2 using a solid phase binding assay. Caspr2 was immobilized on 96-well plates. Then contactin-2 was added at concentrations ranging from 0 to 50nM. We found contactin-2 binds immobilized Caspr2 with a K D of 15 6 5nM (Fig 3A) . Alternatively, when contactin-2 is immobilized, Caspr2 binds contactin-2 with a K D of 12 6 7nM (see Fig 3B) . These values are comparable to previously published results and confirm that Caspr2 and contactin-2 bind one another with nanomolar affinity.
22
Caspr2 Autoantibodies Inhibit the Interaction of Caspr2 with Contactin-2 To test our hypothesis that Caspr2 autoantibodies inhibit Caspr2 binding to contactin-2, we immobilized Caspr2 on a 96-well plate, treated with the wells with varying dilutions of anti-Caspr2 case sera, and studied the ability of Caspr2 to bind contactin-2. To control for the effect of nonspecific binding of unrelated antibodies or serum elements, we also tested control sera containing NMDAR antibodies. Results are expressed as fraction of contactin-2 binding compared to no treatment (see Fig 3C) . We found a dose-dependent decrease in contactin-2 binding in the presence of anti-Caspr2 sera, but not with anti-NMDAR sera, supporting our hypothesis that Caspr2 autoantibodies block the interaction of Caspr2 with contactin-2. Subsequently, we tested our remaining anti-Caspr2 case samples for their ability to inhibit binding to contactin-2. Each anti-Caspr2 sample inhibited the interaction of Caspr2 with contactin-2, although to varying degrees, ranging from 33 6 12 to 91 6 2% inhibition, compared to control sera-either pooled CMT sera (3.6 6 8.1%) or an anti-NMDAR serum (8.5 6 3.2%; see Fig 3D) . Interestingly, sample C2 showed the strongest inhibition, although it contained IgG2 > IgG4 antiCaspr2 antibodies; however, sample C2 also showed the strongest reactivity to Caspr2 in general, so a higher titer of this antibody may explain the increased inhibition. These experiments demonstrate that Caspr2 autoantibodies consistently inhibit the interaction of Caspr2 with contactin-2.
Caspr2 Autoantibodies Do Not Affect Surface Expression of Caspr2
We used cultured rat hippocampal neurons to study surface expression levels of Caspr2. Immunostaining of live 14 to 21 days in vitro cultures for Caspr2 revealed punctate staining of axons in neurons (Fig 4A) , in accord with predominantly axonal membrane localization found by Pinatel et al. 15 To determine whether Caspr2 autoantibodies cause internalization of the antigen in a manner comparable to NMDAR antibodies, 11 rat hippocampal neurons were treated with either anti-Caspr2 sera or control sera from CMT cases for 24 hours. This time point was chosen based on previous results demonstrating that NMDAR antibodies cause maximal internalization at 12 hours and this effect remains for at least 48 hours. 11 Living hippocampal neurons were labeled with an antibody to the extracellular domain of Caspr2 (surface Caspr2), fixed and permeabilized, and then labeled with an antibody that is a cytoplasmic epitope of Caspr2 (total Caspr2). We found no difference in density of Caspr2 puncta in samples treated with Caspr2 antisera versus control (CMT) sera tested at a concentration of 1:100 (see Fig 4E) . The vast majority of Caspr2 was expressed on the cell surface in both treated and control samples, as there was only a minor amount of total Caspr2 that did not colocalize with surface Caspr2 (data not shown). Neurons were also treated with anti-Caspr2 or control sera at a concentration of 1:25 (see Fig 4F) . Again, no difference in Caspr2 puncta density was observed, although there was considerable cell death in both the treatment and control groups at the higher sera concentration. Additionally, there was no difference in puncta intensity or puncta area in the treatment versus control samples at either sera concentration (data not shown).
To confirm that Caspr2 autoantibodies do not cause internalization of Caspr2, cell-surface biotinylation experiments were performed. HEK293 cells transfected to express Caspr2 were treated with either anti-Caspr2 sera or control (CMT) sera for 24 hours, then treated with biotin conjugated to a sulfhydryl moiety, lysed with RIPA buffer, and mixed with avidin-conjugated resin to separate cell surface Caspr2 from Caspr2 located inside the cell. There was no difference in biotinylated (cell surface) Caspr2 in anti-Caspr2 sera-treated samples versus control samples (Fig 5) . There was also no difference in unbiotinylated (internalized) Caspr2 or total Caspr2 protein levels. Because only a fraction of surface Caspr2 was probably biotinylated, this approach may underestimate the amount of surface Caspr2 and overestimate the amount of internalized Caspr2, but this should be consistent across samples. These results demonstrate that antiCaspr2 sera do not affect cell surface levels of Caspr2 in 2 model systems.
Discussion
Our findings demonstrate a functional effect of Caspr2 autoantibodies and provide a potential pathogenic mechanism. We show that Caspr2 autoantibodies do not function like NMDAR and AMPAR autoantibodies, which result in the internalization of the targeted receptors; this is thought to be a primary mechanism in the pathophysiology of antibody-mediated autoimmune disorders. [9] [10] [11] 14 Caspr2 autoantibodies, in contrast, do not result in the internalization of Caspr2. This may be due to differences in the membrane trafficking of Caspr2 compared to ionotropic receptors and/or a lack of crosslinking by Caspr2 IgG4 antibodies, which are functionally monovalent. Notably, monovalent (Fab) fragments of autoantibodies to NMDAR and AMPAR also fail to internalized these receptors. 10 Because the primary known function of Caspr2 is to act as a CAM, we hypothesized that Caspr2 autoantibodies inhibit its interaction with its binding partner contactin-2, which we demonstrated directly. All 6 anti-Caspr2 sera inhibited the interaction of Caspr2 with contactin-2, but the degree of inhibition varied. The reasons that some of the anti-Caspr2 autoantibodies inhibited binding more than others are likely 2-fold. First, some of the autoantibodies reacted to Caspr2 more avidly than others. For instance, sample C2 had the strongest reactivity to Caspr2 and robustly inhibited binding to contactin-2. Conversely, sample C5 also had a very high titer and showed the least amount of inhibition, and sample C4 had a low titer but showed robust inhibition. These results demonstrate that the antibody titer cannot completely account for the degree of inhibition observed. Second, the epitopes of the autoantibodies also likely play a role. We and others have previously shown that autoantibodies recognize multiple epitopes concentrated at the N-terminus of the Caspr2. 15, 24 For instance, the epitopes of C5 and C6 were previously mapped by Olsen et al. 24 These samples (as well as most of the anti-Caspr2 samples tested) recognize the discoidin domain as well as other epitopes concentrated in the N- 
CMT 5 Charcot-Marie-Tooth disease.
terminus of the protein. It is unclear how binding of IgG4 antibodies to these domains would inhibit binding to contactin-2; the regions for binding for contactin-2 have yet to be determined, and antibodies to these regions will likely result in stronger inhibition. A limited amount of patient sample prevented epitope mapping of the remaining patient samples used in this paper.
Our work confirms that Caspr2 and contactin-2 bind one another with nanomolar affinity. Whether Caspr2 binds contactin-2 in cis and/or in trans is a matter of debate. Traka et al previously published that contactin-2-Fc chimeric protein did not bind to cells transfected with Caspr2 alone, whereas it interacted with cells cotransfected with Caspr2 and contactin-2, 8 leading to symptoms seen in patients with Caspr2 autoantibodies (peripheral nerve hyperexcitability and neuropathic pain). Admittedly, Caspr2-null mice did not show any abnormalities in nerve conduction despite mislocalization of VGKCs. 7 Whether Caspr2 autoantibodies result in mislocalization of VGKCs and what effects this may have on nerve conduction remain to be elucidated and will be a matter of future investigation. A schematic of our proposed mechanism of pathogenicity for autoantibodies to Caspr2 is presented in Figure 6 . In addition to Caspr2 antibodies, autoantibodies to other CAMs are also predominantly of the IgG4 subtype. 17 For instance, antibodies to neurofascin 155 (NF155), neurofascin 186 (NF186), and contactin-1 were discovered in a subset of patients with chronic and acute inflammatory demyelinating polyneuropathies and prior to the addition of contactin-2. Of note, the Charcot-Marie-Tooth disease (CMT) control sample is a pooled sample of sera from 3 patients with inherited neuropathy. All 6 anti-Caspr2 patient samples (but not the anti-NMDAR sample) significantly inhibited binding of contactin-2 compared to CMT control when analyzed using a 1-way analysis of variance followed by Holm-Sidak post hoc analysis. Error bars represent 6 standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001.
are all predominantly IgG4. 18, [29] [30] [31] [32] [33] [34] [35] [36] [37] These proteins all play critical roles in conduction of action potentials at nodes of Ranvier. At nodes, NF186 interacts with extracellular matrix proteins such as gliomedin and mediates the clustering of voltage-gated sodium channels. [38] [39] [40] At paranodes, NF155 is expressed by the terminal loops of myelin and associates with axonal CAMs contactin-1 and Caspr1 to form septatelike junctions, which prevent current leakage. 41 The mechanism by which autoantibodies to NF155 and NF186 cause disease, assuming they do Neurons were live-stained with a polyclonal anti-Caspr2 antibody to the extracellular domain (surface Caspr2), fixed and permeabilized, and stained with an antibody to the C-terminus of Caspr2 (total Caspr2), and puncta were quantified. Boxed areas are magnified for neurons treated with (C) Caspr2 sera and (D) control sera. (E) There was no difference in Caspr2 puncta density (aggregate of 2 patient samples and 2 control samples). (F) The experiment was repeated with a sera dilution of 1:25. Again, no difference in Caspr2 puncta density was observed. Results were compared using a 2-tailed t test. Error bars represent 6 standard error of the mean. Scale bars 5 40 mm.
so, remains to be elucidated. Autoantibodies to contactin-1, on the other hand, were found to disrupt the interaction of contactin-1 with NF155/Caspr1 at the paranode. 31, 32 Other examples of IgG4 autoantibodies that associate with neurologic diseases are anti-leucine-rich gliomainactivated1 (LGI1), which is associated with encephalitis, and anti-muscle-specific tyrosine kinase (MuSK) antibodies found in a subset of patients with myasthenia gravis. 17 MuSK antibodies were found to prevent binding of MuSK to Lrp4 and collagen Q, which in turn inhibits agrin-stimulated MuSK phosphorylation. [42] [43] [44] LGI1 antibodies were discovered to inhibit binding to ADAM22 which, in turn, reduced synaptic AMPARs. 45 Together, these data and our work suggest that blocking proteinprotein interactions may be a common mechanism of IgG4 autoantibodies, particularly those targeting CAMs. To date, the largest cohort of anti-Caspr2 patients studied consisted of a retrospective analysis of 38 cases. 4 Treatments utilized included steroids, intravenous immunoglobulin, plasma exchange, azathioprine, cyclophosphamide, and/or rituximab. Full recovery occurred in 39% and a partial response was seen in 52%, although 25% of patients had a clinical relapse. Due to the rarity of this disease, no head-to-head comparisons of the above treatments have been carried out. A potential therapeutic strategy for these diseases would be to reduce IgG4-producing B cells. In support of this, rituximab, a monoclonal antibody against CD20, has been shown to be effective in the treatment of anti-MuSK myasthenia gravis and anti-LGI1 limbic encephalitis with long-term remission. [46] [47] [48] Similarly, there are reported cases of good treatment response to rituximab in otherwise treatmentrefractory anti-Caspr2 autoimmune encephalitis. 2, 49 Strategies directed at other components of the immune system (eg, inhibiting complement or T-cell therapies), however, may not be effective.
